Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. GFA Production Xiamen Co., Ltd.
WARNING LETTER
•GFA Production Xiamen Co., Ltd.•December 8, 2023

GFA Production Xiamen Co., Ltd. – FDA Warning Letter, Dec 8, 2023

Record Details

The FDA inspected GFA Production Xiamen Co., Ltd. in Xiamen, China, from December 4-8, 2023, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B). The firm's December 28, 2023, response to the Form FDA 483 was deemed inadequate. Key violations include the failure to establish and follow adequate written procedures for production and process control (21 CFR 211.100(a) and (b)), specifically citing a lack of process validation, inadequate cleaning validation, and insufficient equipment controls. Additionally, the firm failed to ensure laboratory records included complete data (21 CFR 211.194(a)), with in-house HPLC testing lacking audit trails and method validation. Lastly, the firm failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)), evidenced by inadequate microbiological methods and a failure to identify routinely observed microorganisms, which is critical given a prior recall for microbiological contamination. The FDA previously placed the firm on Import Alert 55-05 and subsequently on Import Alert 66-40. The firm committed to ceasing drug production at this facility and outsourcing manufacturing, but remains responsible for contract manufacturers. If manufacturing resumes, a qualified consultant and a comprehensive six-system audit are required. The firm must respond within 15 working days with corrective actions, including testing retain samples of all distributed batches within expiry. Failure to comply may result in continued refusal of admission of products and withholding of new application approvals.

Company
GFA Production Xiamen Co., Ltd.
Inspection date
December 8, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 6d754766-2d37-445a-a500-a7d001947e95

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.100(a)21 CFR 211.100(b)21 CFR 211.194(a)21 CFR 211.160(a)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for GFA Production Xiamen Co., Ltd.
  • 483 - 2023-12-08December 8, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GFA Production Xiamen Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.